Impact of Tuberculosis on Disease Severity and Viral Shedding Duration in COVID-19 Patients
Accumulating evidence show a potential association between tuberculosis and COVID-19 disease severity. To further clarify the impact of tuberculosis on COVID-19 disease severity and viral shedding duration, a retrospective study was conducted on 223 COVID-19 patients, including 34 with tuberculosis and 189 without tuberculosis. Clinical information and viral load shedding time were collected. A higher percentage of severe/critical COVID-19 diagnosis and deaths was observed in patients with tuberculosis than in those without tuberculosis (8.8% vs. 3.2%, p = 0.142; 2.9% vs. 1.1%, p = 0.393), and COVID-19 patients with tuberculosis had longer viral shedding than those without tuberculosis (median: 15.0 days vs. 11.0 days; p = 0.0001). Having tuberculosis (HR = 2.21, 95% CI 1.37-3.00; p = 0.000), being of elderly age (HR = 1.02, 95% CI 1.01-1.03; p = 0.001) and being diagnosed with severe or critical COVID-19 (HR = 5.63, 95% CI 2.10-15.05; p = 0.001) were independent factors associated with prolonged virus time of SARS-CoV-2. COVID-19 patients with tuberculosis receiving anti-tuberculosis therapy time (ATT) for <2 months had a significantly longer virus shedding duration than those receiving ATT for ≥ 4 months (17.5 vs. 11.5 days, p = 0.012). Our results demonstrated that COVID-19 patients with tuberculosis tend to have more severe disease and a worse prognosis, and tuberculosis prolonged viral shedding, highlighting special attention and/or care required for COVID-19 patients with tuberculosis receiving ATT for <2 months.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
---|---|
Enthalten in: |
Viruses - 16(2024), 2 vom: 06. Feb. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Huang, Wei [VerfasserIn] |
---|
Links: |
---|
Themen: |
COVID-19 |
---|
Anmerkungen: |
Date Completed 26.02.2024 Date Revised 27.02.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.3390/v16020260 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368900231 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM368900231 | ||
003 | DE-627 | ||
005 | 20240229164809.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240229s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/v16020260 |2 doi | |
028 | 5 | 2 | |a pubmed24n1309.xml |
035 | |a (DE-627)NLM368900231 | ||
035 | |a (NLM)38400036 | ||
035 | |a (PII)260 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Huang, Wei |e verfasserin |4 aut | |
245 | 1 | 0 | |a Impact of Tuberculosis on Disease Severity and Viral Shedding Duration in COVID-19 Patients |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.02.2024 | ||
500 | |a Date Revised 27.02.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Accumulating evidence show a potential association between tuberculosis and COVID-19 disease severity. To further clarify the impact of tuberculosis on COVID-19 disease severity and viral shedding duration, a retrospective study was conducted on 223 COVID-19 patients, including 34 with tuberculosis and 189 without tuberculosis. Clinical information and viral load shedding time were collected. A higher percentage of severe/critical COVID-19 diagnosis and deaths was observed in patients with tuberculosis than in those without tuberculosis (8.8% vs. 3.2%, p = 0.142; 2.9% vs. 1.1%, p = 0.393), and COVID-19 patients with tuberculosis had longer viral shedding than those without tuberculosis (median: 15.0 days vs. 11.0 days; p = 0.0001). Having tuberculosis (HR = 2.21, 95% CI 1.37-3.00; p = 0.000), being of elderly age (HR = 1.02, 95% CI 1.01-1.03; p = 0.001) and being diagnosed with severe or critical COVID-19 (HR = 5.63, 95% CI 2.10-15.05; p = 0.001) were independent factors associated with prolonged virus time of SARS-CoV-2. COVID-19 patients with tuberculosis receiving anti-tuberculosis therapy time (ATT) for <2 months had a significantly longer virus shedding duration than those receiving ATT for ≥ 4 months (17.5 vs. 11.5 days, p = 0.012). Our results demonstrated that COVID-19 patients with tuberculosis tend to have more severe disease and a worse prognosis, and tuberculosis prolonged viral shedding, highlighting special attention and/or care required for COVID-19 patients with tuberculosis receiving ATT for <2 months | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a severity | |
650 | 4 | |a tuberculosis | |
650 | 4 | |a viral shedding | |
650 | 7 | |a RNA, Viral |2 NLM | |
700 | 1 | |a Liu, Ping |e verfasserin |4 aut | |
700 | 1 | |a Yan, Bo |e verfasserin |4 aut | |
700 | 1 | |a Zheng, Fang |e verfasserin |4 aut | |
700 | 1 | |a Yang, Yang |e verfasserin |4 aut | |
700 | 1 | |a Xi, Xiuhong |e verfasserin |4 aut | |
700 | 1 | |a Xia, Lu |e verfasserin |4 aut | |
700 | 1 | |a Shen, Yinzhong |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Viruses |d 2009 |g 16(2024), 2 vom: 06. Feb. |w (DE-627)NLM192382764 |x 1999-4915 |7 nnns |
773 | 1 | 8 | |g volume:16 |g year:2024 |g number:2 |g day:06 |g month:02 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/v16020260 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 16 |j 2024 |e 2 |b 06 |c 02 |